Ashina M, Goadsby PJ, Dodick DW, et al. - In patients with migraine with and without history of aura, reduced migraine frequency and fewer days of acute migraine-specific medication use were achieved with erenumab treatment than placebo. Overall, erenumab could afford a safe and effective treatment option for patients with migraine with and without history of aura.

• In this post hoc secondary analysis of 4 randomized clinical trials, a total of 2682 adults aged 18 to 65 years with episodic migraine or chronic migraine who were randomized to receive either erenumab or placebo [52.2% received 1 or more dose of erenumab, 70 mg or 140 mg, and 38.9% received placebo], were analyzed.

• Erenumab treatment resulted in greater reductions from baseline monthly migraine days (MMDs) and acute migraine–specific medication days, than placebo, in patients with and without a history of aura.

• With erenumab, 70 mg, and 140 mg, least-squares mean differences in change from baseline MMDs at week 12 were –1.1 and –0.9 respectively, vs placebo, in those with episodic migraine and a history of aura.

• In cases with chronic migraine with a history of aura, the least-squares mean differences from placebo treatment were –2.1 in those treated with erenumab, 70 mg, and –3.1 with erenumab, 140 mg.

• No differences were seen in the safety profiles of patients in either group.